Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants.

@article{ClementsMann1999SafetyAI,
  title={Safety and immunogenicity of live attenuated human-bovine (UK) reassortant rotavirus vaccines with VP7-specificity for serotypes 1, 2, 3 or 4 in adults, children and infants.},
  author={Mary Lou Clements-Mann and M K Makhene and Jacek Mrukowicz and Peter Farnum Wright and Yasutaka Hoshino and Karen Midthun and Ellen F Sperber and Ruth A. Karron and Albert Z. Kapikian},
  journal={Vaccine},
  year={1999},
  volume={17 20-21},
  pages={
          2715-25
        }
}
Live rotavirus vaccine candidates representing VP7 serotypes 1, 2, 3 or 4 derived by reassortment between bovine UK rotavirus and human rotavirus strains D, DS-1, P or ST3 were evaluated for safety and immunogenicity in adults, children and infants. Infection was defined by evidence of rotavirus shed in stools or a 4-fold or greater increase in serum rotavirus-specific IgA or IgG ELISA or plaque reduction neutralization antibody. A single oral dose (10(5.3) or 10(5.8) pfu) of reassortant virus… CONTINUE READING